NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.

Don't have an account? Subscribe

Movements in melanoma management

By Pat Kelly - 25th Jun 2023

In his talk at the Irish Melanoma Forum 11th Annual Scientific Meeting, Prof Paul Lorigan, Professor of Medical Oncology at the University of Manchester, discussed research and treatment advances in melanoma management, providing an overview of data from some key trials, including KEYNOTE and CHECKMATE76K. “There is a need for other trials and one of my take-home messages is that management shouldn’t be just immunotherapy, or more immunotherapy; we do need to have the option of targeted therapy,” said Prof Lorigan. “Many patients are not suitable for immunotherapy, perhaps because of connective tissue disease, or younger people in particular may be concerned about [longer-term immunotherapy] affecting their fertility, for example.”  

He presented data from other studies, some of which are still in the recruitment stage, and he also briefly discussed de-escalation strategies, as well as the potential benefits of neoadjuvant therapy. “When you think about it, it makes sense,” Prof Lorigan told the conference. “When you remove the tumour, there is less there for the immune system to recognise when you give your adjuvant therapy to prime your immune system; so fewer antigens, fewer T-cells and lower response. If you leave the tumour in for a period of time, you allow the immune system to see it when we give a PD1 inhibitor, then we remove the tumour, but you have lots of expanded tumour-recognising T-cells left behind. That’s the theory and in practise, that’s what happens.”

Prof Lorigan said that there have been exciting advances in stage II disease management, but there remains a need to refine these advances and improve on patient selection. “I think neoadjuvant therapy is on the cusp of being approved as the standard of care,” he told the delegates. “In the metastatic setting, immunotherapy is the standard of care and in the first-line setting for the majority of patients, it’s hard to beat. Also, personalised treatment based on targeting neoantigens has huge potential and is likely to be one of the next developments coming down the line.”

Leave a Reply

Latest Issue
medical independent 5th December
The Medical Independent 5th December 2023

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read